ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.343,95
0,12%
S&P 500
5.918,25
0,00%
Dow Jones
42.635,20
0,00%
Euro vs US Dollar
1,03034
0,06%
Bitcoin
94.824,37
2,61%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. INVO BioScience Inc (INVO)

  7. INVO BioScience Inc (INVO) News

INVO

INVO BioScience (INVO)

INVO BioScience Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INVO
DatumZeitQuelleÜberschriftSymbolFirma
24/10/202415h00GlobeNewswire Inc.NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaNASDAQ:INVOINVO BioScience Inc
22/10/202418h05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:INVOINVO BioScience Inc
21/10/202415h00GlobeNewswire Inc.INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesNASDAQ:INVOINVO BioScience Inc
15/10/202415h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
14/10/202415h18GlobeNewswire Inc.INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)NASDAQ:INVOINVO BioScience Inc
01/10/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
20/09/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
18/09/202423h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
14/08/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
14/08/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVOINVO BioScience Inc
14/08/202415h00GlobeNewswire Inc.INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDANASDAQ:INVOINVO BioScience Inc
21/05/202422h39Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INVOINVO BioScience Inc
15/05/202422h51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
15/05/202422h15GlobeNewswire Inc.INVO Reports Record First Quarter 2024 Financial ResultsNASDAQ:INVOINVO BioScience Inc
06/05/202423h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
17/04/202416h25AllPennyStocks.comMicro Cap Massively Bid Up Before Opening BellNASDAQ:INVOINVO BioScience Inc
16/04/202422h59GlobeNewswire Inc.INVO Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:INVOINVO BioScience Inc
06/02/202416h24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVOINVO BioScience Inc
01/02/202415h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
23/01/202414h00GlobeNewswire Inc.NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)NASDAQ:INVOINVO BioScience Inc
17/01/202414h00GlobeNewswire Inc.INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsNASDAQ:INVOINVO BioScience Inc
16/01/202423h29Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:INVOINVO BioScience Inc
10/01/202422h46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:INVOINVO BioScience Inc
10/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
03/01/202423h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
28/12/202323h04Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:INVOINVO BioScience Inc
28/12/202323h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
13/12/202323h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:INVOINVO BioScience Inc
13/12/202322h53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
11/12/202314h00PR Newswire (US)NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalNASDAQ:INVOINVO BioScience Inc
 Showing the most relevant articles for your search:NASDAQ:INVO

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
TG
NOV
Novo Nordisk
TG
RHM
Rheinmetall
CCOM
SILVER
SILVER
COIN
DOGEUSD
Dogecoin
TG
DBK
Deutsche Bank
USOTC
RHHBY
Roche (QX)
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
DBI
MDAX
MDAX
NASDAQ
TSLA
Tesla
TG
432
Arbor Metals
NYSE
KO
Coca Cola
TG
MBG
MercedesBenz
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten